Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | SELE | P16581 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28476853 | 0.87 | KDM4E (0.51) | NPC1KDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL222446 | 0.86 | RXFP1 (0.55) | NPC1RAB9AKDM4ESMN1; SMN2RXFP1 | |
| SCHEMBL29702265 | 0.86 | RXFP1 (0.55) | NPC1RAB9AKDM4ESMN1; SMN2RXFP1 | |
| SCHEMBL5812852 | 0.85 | KDM4E (0.51) | NPC1RAB9AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL14877164 | 0.84 | RXFP1 (0.48) | NPC1RAB9AKDM4ECASP3SENP8 | |
| SCHEMBL6183442 | 0.84 | PDK1 (0.59) | RXFP1CYP2C9BRD9MEN1LMNA | |
| SCHEMBL7607973 | 0.82 | CASR (0.52) | ALDH1A1SMN1; SMN2RXFP1BRD9MEN1 | |
| SCHEMBL5866194 | 0.81 | HSP90AA1 (0.46) | NPC1RAB9AHSD17B10ALDH1A1RXFP1 | |
| SCHEMBL8651106 | 0.81 | ATR (0.47) | NPC1RAB9AKDM4EALDH1A1RXFP1 | |
| SCHEMBL6290067 | 0.81 | ELANE (0.40) | KDM4EHSD17B10PPARGNR1H4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | PHARMACEOPEIA, INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1242385-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | PHARMACOPEIA, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2001047897-A1 | CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS | PHARMACOPEIA, INC. (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1054867-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| US-5958930-A | TREATING CANCER, AND SECONDARY INFECTIONS CAUSED BY PNEUMOCYSTIS CARINII AND TOXOPLASMOSIS GONDII IN IMMUNOCOMPROMISED PATIENTS. | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-09-28 | — | — | US | disclosed |
| US-5939420-A | BACTERICIDES CAUSED BY PNEUMOCYSTIS AND TOXOPLASMOSIS, ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999036406-A1 | ANTIVIRALS | MEDIVIR AB (SE) | 1999-07-22 | — | — | WO | disclosed |
| US-5877178-A | AIDS THERAPY | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-03-02 | — | — | US | disclosed |
| US-5863920-A | ANTICARCINOGENIC AGENTS AND BACTERICIDES | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 1999-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885 |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | NPC1 3085/4885RAB9A 2793/4885KDM4E 3517/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885 |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | NPC1 3085/4885RAB9A 2793/4885KDM4E 3517/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.